Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNM NASDAQ:NTLA NASDAQ:PROK NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$18.74$21.44$7.96▼$27.65$2.12B2.041.33 million shs3.32 million shsNTLAIntellia Therapeutics$15.67$13.78$7.95▼$28.25$2.19B1.926.43 million shs8.84 million shsPROKProKidney$1.83$1.83$0.54▼$7.13$552.77M1.64878,263 shs578,008 shsZLABZai Lab$18.18$19.72$15.96▼$41.20$2.06B0.78904,808 shs978,129 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome0.00%+1.96%-18.38%-6.40%+112.23%NTLAIntellia Therapeutics0.00%+29.40%+26.68%+22.04%+63.23%PROKProKidney0.00%+11.59%+4.57%-5.18%+162.82%ZLABZai Lab0.00%+6.50%-4.82%+0.50%-50.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$18.74$21.44$7.96▼$27.65$2.12B2.041.33 million shs3.32 million shsNTLAIntellia Therapeutics$15.67$13.78$7.95▼$28.25$2.19B1.926.43 million shs8.84 million shsPROKProKidney$1.83$1.83$0.54▼$7.13$552.77M1.64878,263 shs578,008 shsZLABZai Lab$18.18$19.72$15.96▼$41.20$2.06B0.78904,808 shs978,129 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome0.00%+1.96%-18.38%-6.40%+112.23%NTLAIntellia Therapeutics0.00%+29.40%+26.68%+22.04%+63.23%PROKProKidney0.00%+11.59%+4.57%-5.18%+162.82%ZLABZai Lab0.00%+6.50%-4.82%+0.50%-50.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 2.85Moderate Buy$33.1776.98% UpsideNTLAIntellia Therapeutics 2.35Hold$20.4630.55% UpsidePROKProKidney 2.50Moderate Buy$7.40304.37% UpsideZLABZai Lab 2.63Moderate Buy$45.83152.11% UpsideCurrent Analyst Ratings BreakdownLatest PROK, NTLA, IMNM, and ZLAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.006/15/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$30.006/12/2026IMNMImmunome WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$31.006/4/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $37.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.005/28/2026IMNMImmunome BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$6.94M305.81N/AN/A$5.75 per share3.26NTLAIntellia Therapeutics$67.67M32.35N/AN/A$5.80 per share2.70PROKProKidney$889K621.79N/AN/A($3.36) per share-0.54ZLABZai Lab$460.16M4.48N/AN/A$6.39 per share2.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)ZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%8/6/2026 (Estimated)Latest PROK, NTLA, IMNM, and ZLAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A21.6821.68NTLAIntellia TherapeuticsN/A6.106.10PROKProKidneyN/A9.069.06ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%NTLAIntellia Therapeutics88.77%PROKProKidney51.59%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipIMNMImmunome7.21%NTLAIntellia Therapeutics3.50%PROKProKidney39.83%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome40113.25 million105.09 millionOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableZLABZai Lab1,784113.41 million107.88 millionOptionablePROK, NTLA, IMNM, and ZLAB HeadlinesRecent News About These CompaniesZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine CarcinomasJune 16, 2026 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 15, 2026 | americanbankingnews.comPfizer, Zai Lab win China nod for cervical cancer therapy TivdakJune 9, 2026 | msn.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJune 8, 2026 | businesswire.comZai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?June 6, 2026 | finance.yahoo.comZai Lab (ZLAB) Announces Senior Leadership ChangesJune 6, 2026 | finance.yahoo.com5 Stocks That Have the Potential to Rise 1000%June 5, 2026 | insidermonkey.comZai Lab (ZLAB) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab Announces Changes to Senior Leadership TeamMay 21, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 11, 2026 | finance.yahoo.comZai Lab wins FDA fast track status for cancer drug Zocilurtatug PelitecanMay 11, 2026 | msn.comZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)May 11, 2026 | businesswire.comZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7, 2026 | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePROK, NTLA, IMNM, and ZLAB Company DescriptionsImmunome NASDAQ:IMNM$18.74 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$18.64 -0.09 (-0.51%) As of 06/18/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Intellia Therapeutics NASDAQ:NTLA$15.67 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$15.62 -0.05 (-0.35%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.ProKidney NASDAQ:PROK$1.83 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.78 -0.06 (-3.01%) As of 06/18/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Zai Lab NASDAQ:ZLAB$18.18 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$18.02 -0.16 (-0.85%) As of 06/18/2026 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
